Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1Phase 1 1

Status

Recruiting 5Completed 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Other solid neoplasm 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Recurrence 1Neoadjuvant Treatment for Locally Advanced Cervical Cancer 1Metastatic Solid Tumors 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

Specimen Handling 482pembrolizumab 454Magnetic Resonance Spectroscopy 419Carboplatin 321Cyclophosphamide 314Biopsy 272Cisplatin 264Radiotherapy 241Paclitaxel 226Gemcitabine 224Bevacizumab 212Nivolumab 189fludarabine 183venetoclax 172Drug Therapy 166Dexamethasone 157Blood Specimen Collection 156Oxaliplatin 154Injections 152Capecitabine 152Fluorouracil 144Docetaxel 143Standard of Care 136Radiosurgery 136Rituximab 125Pemetrexed 115durvalumab 113atezolizumab 110Leucovorin 110Radiation 105

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Infusions, Intravenous × 1 year × Clear all
NCT07530445 2026-04-15

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

Sun Yat-sen University

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07108114 2026-02-23

SLV-324 Treatment of Metastatic Solid Tumors

Solve Therapeutics

Phase 1 Recruiting
70 enrolled
Other solid neoplasm

Metastatic Solid Tumors

NCT07286253 2025-12-16

QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Phase 2 Recruiting
50 enrolled
Gynecologic

Neoadjuvant Treatment for Locally Advanced Cervical Cancer

NCT07243691 2025-11-24

Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma

Sir Run Run Shaw Hospital

Phase NA Recruiting
33 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03850574 2025-08-26

TUSCANY

Aptose Biosciences Inc.

Phase 1/2 Recruiting
240 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡